Loading clinical trials...

Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland

Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial

NCT04364022•Calmy Alexandra

View on ClinicalTrials.gov

Summary

A study to assess, in a two-arm open-label cluster randomized clinical trial, the efficacy of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient, compared to surveillance alone.

Eligibility

Age

16 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Documented close contact with a person with either a PCR-confirmed SARS-CoV-2 or a positive rapid SARS-CoV-2 antigen test (as per standard of care).
•2. Enrolment of the participant no more than 7 days since last contact with index case;
•3. ≥ 16 years of age;
•4. Informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.).

Exclusion Criteria

•1. Fever (temperature \>38.0°C) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia;
•2. Individuals with previous confirmed SARS-CoV-2 infection, dating within the last six months ;
•3. Known impairment of liver function;
•4. Known hypersensitivity to the study medications;
•5. Use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker
•6. Individuals on boosted protease inhibitor (other than LPV) or boosted elvitegravir as part of an antiretroviral therapy
•7. Inability to be followed-up for the trial period
•8. Documented vaccination against SARS-CoV-2
•* Where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

Locations (4)

Instituto Nacional de Infectiologia Evandro Chagas, Fiocruz

Rio de Janeiro, Brazil

Universitätsspital Basel and SwissTPH

Basel, Switzerland

Hôpitaux Universitaires de Genève

Geneva, Switzerland

Ospedale Regionale di Lugano

Lugano, Switzerland

Key Dates

Start Date

April 23, 2020

Primary Completion Date

March 24, 2021

Completion Date

March 24, 2021

Last Updated

April 12, 2021

Enrollment

326

ACTUAL participants

Conditions

Prevention of COVID-19

Interventions

Lopinavir/ritonavir

DRUG

Assessing Immune Response of Different COVID-19 Vaccines in Older Adults

NCT05160766

Prevention of COVID-19

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions